Form 4 for CRL Charles River Laboratories
Accepted 2023-05-31 00:00:00 ET · period of report 2023-05-26 · accession 0001127602-23-017137 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-05-31 | 2023-05-29 | CRL | FOSTER JAMES C | COB, Pres, CEO, Dir | F - Tax | $194.12 | -1,274 | 199.5K | -0.6% | -$247.3K |
| D | 2023-05-31 | 2023-05-26 | CRL | FOSTER JAMES C | COB, Pres, CEO, Dir | A - Grant | $194.12 | +28.2K | 28.2K | New | +$5.47M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-29 | F | D | 1,274 | $194.12 | 199,523 | D | — | — | |
| 2 | Derivative | Stock Options (Right to Buy) | 2023-05-26 | A | A | 28,176 | $194.12 | 28,176 | D | $194.12 · 2024-05-26 to 2033-05-26 | 28,176 Common Stock | (F1) Stock Options vest as follows: 7,044 on May 26, 2024, 7,044 on May 26, 2025, 7,044 on May 26, 2026 and 7,044 on May 26, 2027. |